welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical Trials
source: Recent Results in Cancer Research
year: 2013
authors: Garcia Rodriguez L A, Cea-Soriano L, Tacconelli S, Patrignani P
summary/abstract:This chapter briefly summarizes the current knowledge about the role of nonsteroidal anti-inflammatory drugs (NSAIDs), specially focusing on those selective for cyclooxygenase (COX)-2 (coxibs), on colorectal cancer (CRC) onset, and progression. Both epidemiological and experimental studies have reported that these drugs reduce the risk of developing colonic tumors. However, the promising use of coxibs in chemoprevention was halted abruptly due to the detection on enhanced cardiovascular (CV) risks. Thus, we discuss the clinical data and plausible mechanisms of CV hazards associated with traditional NSAIDs and coxibs. The extent of inhibition of COX-2-dependent prostacyclin, an important vasoprotective and anti-thrombotic pathway, in the absence of a complete suppression of COX-1-dependent platelet function, at common doses of NSAIDs, might play a role in CV toxicity. Coxibs might still be reserved for younger patients with familial adenomatous polyposis (FAP). However, it should be taken into consideration that recent findings of enhanced thromboxane (TX)A(2) biosynthesis in colon tumorigenesis, detected in humans. In this context, the use of low-dose aspirin (which mainly acts by inhibiting platelet COX-1-dependent TXA(2)) may have a place for chemoprevention of CRCs (see also Chap. 3 ). The possible use of coxibs to prevent CRC will depend mainly on research progresses in biomarkers able to identify the patients uniquely susceptible to developing thrombotic events by inhibition of COX-2.
organization: Centro Español de Investigacion FarmacoepidemiologicaDOI: 10.1007/978-3-642-30331-9_4
read more
expertly curated content related to this topic
-
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of...This phase II trial studies the side eff...
-
Polyposis Syndromes of the Colon Current Management, Controversies and Future Directionhttp://www.slideserve.com/verena/polypos...
-
Bonnies Diary March 08https://jtvcancersupport.com/embed/46053...
-
Clinical End Points for Developing Pharmaceuticals to Manage Patients with a Sporadic or Genetic Risk of Colorectal ...To reduce the morbidity and mortality fr...
-
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors̵...Colorectal cancer (CRC) is a leading cau...
-
Nonsteroidal Anti-Inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical IssuesNumerous experimental, epidemiologic, an...
-
Aspirin and Familial Adenomatous Polyposis: Coming Full CircleThis perspective discusses the clinical ...